Recent News

• 06.09.2025 - PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC
• 06.02.2025 - PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
• 05.22.2025 - PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
• 05.14.2025 - PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
• 05.09.2025 - PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 06.02.2025 - EX-99.1 EX-99.1
• 06.02.2025 - 8-K Current report
• 05.27.2025 - S-3 Registration statement under Securities Act of 1933
• 05.22.2025 - 8-K Current report
• 05.22.2025 - EX-99.1 EX-99.1
• 05.22.2025 - DEFR14A Revised definitive proxy soliciting materials
• 05.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.14.2025 - 8-K Current report
• 05.14.2025 - EX-99.1 EX-99.1